# A Study of SHR-A1811 in Subjects With Ovarian Cancer

Source: https://onco.cc/trials/nct06828354/  
OnCo record `nct06828354` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Trastuzumab rezetecan, Paclitaxel / nab-paclitaxel, Gemcitabine in ovarian cancer, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.

## Summary

A Study of SHR-A1811 in Subjects With Ovarian Cancer is a phase 3 interventional study registered as NCT06828354 by Jiangsu HengRui Medicine Co., Ltd., with 300 participants planned, started 2025-03-13 and due to reach its primary completion in 2027-05. Interventions recorded: SHR-A1811, Paclitaxel Injection, Doxorubicin Hydrochloride Liposome Injection, Gemcitabine Hydrochloride for Injection, Topotecan Hydrochloride for Injection. Conditions listed: Ovarian Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06828354
- Phase: 3
- Setting: An Open-label, Randomized, Multicenter Phase III Clinical Trial of SHR-A1811 Versus Investigator-selected Chemotherapy for Platinum-resistant Relapsed Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Enrolled: 300

## Sources

- ClinicalTrials.gov NCT06828354: https://clinicaltrials.gov/study/NCT06828354

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Topotecan](https://onco.cc/drugs/topotecan/), [Trastuzumab rezetecan](https://onco.cc/drugs/trastuzumab-rezetecan/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct06828354.json